Background: Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by an associate degree of autoimmune-mediated destruction of platelets and a proportionately elevated risk of loss of blood. Romiplostim is a Thrombopoietin receptor agonist (TPO-RA) that binds and activates the TPO receptor (c-MPLl) on megakaryocytes and their precursors, resulting in increased platelet production.

Methodology: This is a prospective observational study to evaluate the safety and efficacy of Romiplostim administration in patients with Immune Thrombocytopenic Purpura. Total of 66 patients were enrolled and are on a therapy with Romiplostim at a specific dose with varying frequency based on their complete blood picture that supports the estimation of platelet count. The patient data was gathered and documented for analysis.

Results: Amongst a total of 66 ITP patients, Females were 68% and Males 32%, whereas the highly affected age group was between 21-40 years. We observed that the Peak Platelet Count (PPC) on an average was maintained in the range of 50,000 to 2,50,000cells/cumm with Romiplostim therapy.

Conclusion: From our study, we concluded that 18% were on first line therapy and 35% were on combination therapy (first and second line agents without Romiplostim). Patients who are intolerant were treated with Romiplostim (47%) showed an effective therapeutic outcome without any significant side effects.

Keywords: Immune thrombocytopenic purpura, Romiplostim, Thrombopoietin receptor agonist, Platelets, Auto immune disorder

Abbreviations: ITP: Immune Thrombocytopenic Purpura; TPO-RA: Thrombopoietin receptor agonist; c-MP: Cytokine receptor Myeloproliferative Leukaemia; PPC: Peak Platelet Count